Skip to main content
SpringerLink
Log in

Bivalirudin

A Pharmacoeconomic Profile of its Use in Patients with Acute Coronary Syndromes

  • Adis Pharmacoeconomic Drug Profile
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Bivalirudin (Angiox®; Angiomax®), a direct thrombin inhibitor, is an intravenous anticoagulant. The efficacy of bivalirudin in the management of patients with non-ST-segment elevation acute coronary syndromes (NSTEACS) or ST-segment elevation myocardial infarction (STEMI) planned for invasive interventions has been shown in large, pivotal, open-label trials. Bivalirudin provided similar ischaemic protection to heparin plus a glycoprotein (GP) IIb/IIIa inhibitor, but with a significant reduction in bleeding events, in patients with NSTE-ACS planned for urgent or early intervention and those with STEMI planned for primary percutaneous coronary intervention (PCI). Mortality rates were also significantly lower in patients with STEMI receiving bivalirudin than in those receiving heparin plus a GP IIb/IIIa inhibitor in the key trial of patients with STEMI.

Based on this clinical data, modelled cost-utility analyses from the perspective of various UK NHS providers have predicted that bivalirudin would be highly likely to be cost effective with regard to the cost per QALY gained relative to a heparin plus GP IIb/IIIa inhibitor-based strategy over a lifetime horizon in these patient populations. In patients with NSTE-ACS planned for urgent or early invasive intervention, a bivalirudin-based strategy was considered to be cost effective in the UK, Scotland and Wales. In patients with STEMI planned for primary PCI, a bivalirudin-based strategy was dominant in the UK and Scotland. Parallel and sensitivity analyses demonstrated that base-case conclusions were robust over a range of plausible changes in parameter estimates and assumptions, including changes made to more closely reflect current local clinical practice.

In addition, budgetary impact analyses in several countries suggested that the implementation of a bivalirudin-based strategy, instead of a heparin plus GP IIb/IIIa inhibitor-based strategy, would be cost saving from a hospital perspective in patients with NSTE-ACS undergoing urgent or early PCI, as well as in patients with STEMI undergoing primary PCI. Likewise, prospective and retrospective treatment cost studies in the US indicated that treatment with bivalirudin was less costly than treatment with heparin plus a GP IIb/IIIa inhibitor in these indications.

In conclusion, available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of strategies based on bivalirudin over those based on heparin plus a GP IIb/IIIa inhibitor in patients with NSTE-ACS planned for urgent or early invasive intervention or STEMI planned for primary PCI. These pharmacoeconomic advantages primarily reflect that, relative to heparin plus a GP IIb/IIIa inhibitor, bivalirudin is associated with lower rates of bleeding over the short term, and is associated with lower rates of early mortality that are subsequently maintained over the longer term in patients with STEMI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. White HD, Chew DP. Acute myocardial infarction Lancet 2008; 372 (9638): 570–84

    Article  PubMed  CAS  Google Scholar 

  2. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008 Dec; 29 (23): 2909–45

    Article  PubMed  Google Scholar 

  3. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Eur J Heart 2007; 28 (13): 1598–660

    Article  CAS  Google Scholar 

  4. Coons JC, Battistone S. 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. Ann Pharmacother 2008 Jul; 42 (7): 989–1001

    Article  PubMed  CAS  Google Scholar 

  5. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl.): 670–707S

    Article  Google Scholar 

  6. Ramanath VS, Eagle KA. Evidence-based medical therapy of patients with acute coronary syndromes. Am J Cardiovasc Drug 2007; 7 (2): 95–116

    Article  CAS  Google Scholar 

  7. National Clinical Guideline Centre for Acute and Chronic Conditions. Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment elevation myocardial infarction. NICE clinical guideline 94. London: National Institute for Health and Clinical Excellence, 2010 Mar

  8. Wijns W, Kohl P, Danchin N, et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010 Oct; 31 (20): 2501–55

    Google Scholar 

  9. Kushner FG, Hand M, Smith SC, et al. 2009 Focused updates: ACC/AHA guidelines for themanagement of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009 Dec 1; 120 (22): 2271–306

    Article  PubMed  Google Scholar 

  10. Manoukian SV. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol 2009 Sep 7; 104 (5 Suppl.): 9–15C

    Article  Google Scholar 

  11. Sobieraj-Teague M, Gallus AS, Eikelboom JW. The risk of iatrogenic bleeding in acute coronary syndromes and longterm mortality. Curr Opin Cardiol 2008 Jul; 23 (4): 327–34

    Article  PubMed  Google Scholar 

  12. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30 (12): 1457–66

    Article  PubMed  Google Scholar 

  13. Angiox 250 mg powder for concentrate for solution of injection or infusion: summary of product characteristics. London: European Medicines Agency, 2010 Feb 12

  14. Angiomax® (bivalirudin) for injection: US prescribing information. Parsippany (NJ): The Medicines Company, 2005 Dec

  15. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001 Dec; 142 (6): 952–9

    Article  PubMed  CAS  Google Scholar 

  16. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995 Sep 21; 333 (12): 764–9

    CAS  Google Scholar 

  17. Schulz S, Mehilli J, Ndrepepa G, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J 2010 Mar; 31 (5): 582–7

    Article  PubMed  CAS  Google Scholar 

  18. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21): 2203–16

    Article  PubMed  CAS  Google Scholar 

  19. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21): 2218–30

    Article  PubMed  CAS  Google Scholar 

  20. Stone GW, Ware GH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007 Dec 5; 298 (21): 2497–506

    Article  PubMed  CAS  Google Scholar 

  21. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009 Oct 3; 374 (9696): 1149–59

    Article  PubMed  Google Scholar 

  22. Stone GW. A prospective, multicenter randomized trial of heparin plus glycoprotein IIb/IIIa inhibitors vs. bivalirudin, and drug-eluting vs. bare metal stents in ST-segment elevation myocardial infarction: final report from the HORIZONS-AMI trial [late-breaking trial abstract]. J Am Coll Cardiol 2010; 56 (13 Suppl. B): xiv. Plus slides presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics; 2010 Sep 21-25; Washington, DC

    Google Scholar 

  23. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004 Aug 11; 292 (6): 696–703

    Article  PubMed  CAS  Google Scholar 

  24. Deeks ED, Curran MP. Bivalirudin: in patients with acute coronary syndromes planned for urgent or early intervention. Drugs 2008; 68 (16): 2345–56

    Article  PubMed  CAS  Google Scholar 

  25. Curran MP. Bivalirudin: in patients with ST-segment elevation myocardial infarction. Drugs 2010 May 7; 70 (7): 909–18

    Article  PubMed  CAS  Google Scholar 

  26. Schwenkglenks M, Brazier JE, Szucs TD, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health 2011 Jan; 14 (1): 24–33

    Article  PubMed  Google Scholar 

  27. Schwenkglenks M, Brazier JE, Szucs TD, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST segment elevation acute coronary syndromes: an analysis for the UK [poster]. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference; 2009 Apr 23-25; Washington, DC

    Google Scholar 

  28. Schwenkglenks M, Szucs TD, Brazier JE, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction: a HORIZONS trial analysis using UK valuations [abstract no. PCV116]. Value Health 2009 Oct 24; 12 (7): A334. Plus poster presented at 12th European Conference on the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-27; Paris

    Article  Google Scholar 

  29. Scottish Medicines Consortium. Bivalirudin 250 mg powder for concentrate for solution for injection or infusion (Angiox): SMC No. (638/10). Glasgow: Scottish Medicines Consortium, 2010 Sep 13

  30. Scottish Medicines Consortium. Bivalirudin, 250mg powder for concentrate for solution for injection or infusion (Angiox®). SMC No. (516/08). Glasgow: Scottish Medicines Consortium, 2008 Nov 7

  31. All Wales Medicines Strategy Group. Final appraisal report: bivalirudin (Angiox®) for the treatment of adult patients with acute coronary syndromes planned for urgent or early intervention. Llandough: All Wales Medicines Strategy Group, 2009 Jun

    Google Scholar 

  32. Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health 2003 Aug; 57: 622–7

    Article  PubMed  CAS  Google Scholar 

  33. Olchanski N, Slawsky K, Fusfeld L, et al. A German hospital budget impact model comparing anticoagulation strategies in percutaneous coronary intervention [abstract no. PCV48]. Value Health 2009 Oct; 12 (7): A321. Plus poster presented at 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2009 May 16-20; Orlando (FL)

    Google Scholar 

  34. Olchanski N, Slawsky K, Cyr P, et al. Clinical and economic impact of bivalirudin on bleeding events in high risk unstable angina (UA)/non-ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) in France [abstract no. PCV43]. Value Health 2010; 13 (3): A157. Plus poster presented at 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15-19; Atlanta (GA)

    Google Scholar 

  35. Olchanski N, Slawsky K, Cyr P, et al. A French hospital budget impact model comparing anticoagulation strategies in primary percutaneous coronary intervention [abstract no. PCV46]. Value Health 2010 May; 13 (3): A158. Plus poster presented at 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15-19; Atlanta (GA)

    Article  Google Scholar 

  36. Olchanski N, Slawsky K, Cyr P, et al. Budget impact of bivalirudin in STEMI patients undergoing primary percutaneous coronary intervention (PPCI) in German hospitals [abstract no. PCV45]. Value Health 2010 May; 13 (3): A157. Plus poster presented at 15th Annual InternationalMeeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15-19; Atlanta (GA)

    Google Scholar 

  37. Olchanski N, Slawsky K, Cyr P, et al. Budget impact of bivalirudin in STEMI patients undergoing primary percutaneous coronary intervention (PPCI) in Italian hospitals [abstract no. PCV44]. Value Health 2010 May; 13 (3): A157. Plus poster presented at 15th Annual InternationalMeeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15-19; Atlanta (GA)

    Google Scholar 

  38. Olchanski N, Slawsky K, Cyr PL, et al. Budget impact of bivalirudin in STEMI patients undergoing primary percutaneous coronary intervention (PPCI) in UK hospitals [abstract no. PCV50]. Value Health 2009 Oct; 12 (7): A321. Plus poster presented at 12th European Conference on the International Society for Pharmacoeconomics and Outcomes Research; 2009 Oct 24-27; Paris

    Google Scholar 

  39. Olchanski N, Slawsky KA, Plent S, et al. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital. Hosp Pract (Minneap) 2010 Nov; 38 (3): 138–46

    Article  Google Scholar 

  40. Pinto DS, Stone GW, Shi C, et al. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. J Am Coll Cardiol 2008; 52 (22): 1758–68

    Article  PubMed  CAS  Google Scholar 

  41. Pinto DS, Ogbonnaya A, Normand S-L. Bivalirudin therapy is associated with improved clinical and economic outcomes in STEMI patients undergoing PCI: results from an observational database [abstract no. 1045-274]. J Am Coll Cardiol 2010; 55 (10 Suppl. 1): A101.E948

    Google Scholar 

  42. Kessler DP. Effect of bivalirudin on economic outcomes of STEMI patients in an observational dataset [abstract no. CV3]. Value Health 2010 May; 13 (3): A11

    Article  Google Scholar 

  43. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2010 Mar; 31 (5): 561–72

    Article  PubMed  CAS  Google Scholar 

  44. Bajaj N, Fan W, Cohen H, et al. Impact of anti-thrombin therapy on hospital cost and length of stay in adult patients undergoing angioplasty [abstract no. TCT-118]. J Am Coll Cardiol 2010; 56 (13 Suppl. B): B28

    Google Scholar 

  45. Garratt KN, Cohen H, Fan W. Mortality reductions linked to bivalirudin use in unselected angioplasty patients with and without bleeding complications [abstract no. TCT-117]. J Am Coll Cardiol 2010; 56 (13 Suppl. B): B28

    Google Scholar 

  46. Lopes RD, Peterson ED, Chen AY, et al. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. JACC: Cardiovasc Interv 2010; 3 (6): 669–77

    Article  Google Scholar 

Download references

Acknowledgements and Disclosures

The manuscript was reviewed by M.E. Bertrand, Lille Heart Institute, University of Lille, Lille, France; M. Möckel, Department of Emergency Medicine and Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany; J.W. Moses, Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, New York, USA; N. Olchanski, Boston Healthcare Associates, Inc., Boston, Massachusetts, USA; M. Schwenkglenks, Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Private Bag 65901, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A. Bivalirudin. Pharmacoeconomics 29, 343–359 (2011). https://doi.org/10.2165/11206360-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11206360-000000000-00000

Keywords

Search

Navigation